Eli Lilly and Company (NYSE:LLY) Holdings Raised by Moss Adams Wealth Advisors LLC

Moss Adams Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 72.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,259 shares of the company’s stock after buying an additional 529 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $734,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $26,000. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $36,000. Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $40,000. Finally, O Brien Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 70.5% in the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after purchasing an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Bank of America lifted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Finally, Truist Financial increased their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Down 0.4 %

Shares of NYSE LLY traded down $2.77 during mid-day trading on Wednesday, reaching $775.00. 2,010,705 shares of the company traded hands, compared to its average volume of 3,076,480. The company’s fifty day moving average is $761.22 and its two-hundred day moving average is $674.88. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78. The stock has a market cap of $736.56 billion, a PE ratio of 114.14, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. During the same period last year, the business posted $1.62 EPS. On average, analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.